Details

Autor(en) / Beteiligte

• Ianevski, Aleksandr
• Yao, Rouan
• Fenstad, Mona Høysæter
• Biza, Svetlana
• Zusinaite, Eva
• Reisberg, Tuuli
• Lysvand, Hilde
• Løseth, Kirsti
• Landsem, Veslemøy Malm
• Malmring, Janne Fossum
• Oksenych, Valentyn
• Erlandsen, Sten Even
• Aas, Per Arne
• Hagen, Lars
• Pettersen, Caroline H.
• Tenson, Tanel
• Afset, Jan Egil
• Nordbø, Svein Arne
• Bjørås, Magnar
• Kainov, Denis E.

Titel

Potential Antiviral Options against SARS-CoV-2 Infection

Ist Teil von

• Viruses, 2020-06, Vol.12 (6), p.642

Ort / Verlag

Basel: MDPI AG

Erscheinungsjahr

2020

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.